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BACKGROUND 
 
 
Pleural effusions are collections of fluid in the pleural spaces. The 
major function of the pleura and the pleural space is to permit the lungs to 
expand and deflate within the chest. Since the pleural space is 
subatmospheric with no barrier to liquid movement the space can occupy 
large volume of fluid. These fluid collections (Pleural effusions) are very 
common clinical entity. 
 
These abnormal collections of pleural fluid in the pleural spaces are 
either because of an increased entry of pleural fluid into the space, a 
decrease in exit of fluid from the space or both. These effusions are quite 
common clinical problems and they are associated with a myriad of clinical 
diseases. 
 
Traditionally pleural effusions are classified into exudates and 
transudates after thoracentesis. Two thirds of pleural effusions are caused by 
congestive cardiac failure, pneumonia, malignancy and pulmonary embolism 
according to literature available. It is of considerable clinical importance to 
differentiate between exudates and a transudates  as the latter does not need 
any treatment . Transudates resolves by itself  where as an exudative pleural 
effusion clearly needs an intervention. 
 
Pleural exudates are secondary to alterations in the capillary 
permeability of the pleura or lymphatic clearance where as transudates are 
due to alterations in the hydrostatic pressure , alterations in the colloid 
osmotic pressure in the capillaries and fluid  entering the pleural cavity from 
the peritoneal cavity through defects in the diaphragm or lymphatics. 
Therefore determining whether the fluid is exudative or transudative   is the 
first step in diagnosing pleural effusions of unknown etiology. In order to 
differentiate between the two, many biochemical parameters have been used 
like protein, sugar, LDH, Bilurubin, cholesterol, ADA, and their respective 
ratios with their  serum values  have been used. A protein level of 3gms/dl 
and LDH level of 200 IU has used as the dividing line between exudates and 
transudates. 
 
Many criteria’s have been used to discriminate between exudates and 
transudate. The one which has used more frequently is the criteria 
introduced by Lights et al1 in 1972.   It was the one which showed improved 
diagnostic efficacy over the other criteria.    
 
Lights criteria1 includes 3 parameters, they are  
 
1) Pleural fluid to serum protein ratio > 0.5 
 
2) Pleural fluid to serum LDH ratio > 0.6 
 
3) Pleural fluid LDH >200 IU of upper limits of normal. 
 
Then later it was found that lights criteria misclassified about 20 to 
30% of pleural  effusions 3. To reduce the misclassifications some 
modifications were made in the lights criteria. Other investigators have 
examined the diagnostic utility of tests that measure pleural fluid cholesterol 
bilirubin and albumin. But they also misclassified significant number of 
pleural effusions and their superiority over the lights criteria in 
discriminating pleural exudates and transudates remained doubtful.  
             
Cholinesterase has been used by a few workers for differentiation 
between pleural exudates and transudates.Cholinesterase activity is 
significantly inhibited in presence of  untreated Pulmonary Tuberculosis 3 
and its activity remained stable in any one individual. Therefore 
measurement of its activity may serve as useful diagnostic tool.  
 
In 1978 Cabrer et al16 estimated Cholinesterase activity in pleural 
effusions of various etiologies and concluded that there exists differences in 
activity of Cholinesterase and it was possible to differentiate transudate and 
exudates. 
 
In 1996 Eduardo et al2 concluded that Pleural fluid to serum 
Cholinesterase ratio was the most accurate criteria for separating exudates 
and transudates and suggested  that it should be used as the first step is 
diagnosis of  pleural effusions, if further studies confirmed their results. 
 
In 1996 Garcia and Padilla4 confirmed the importance of estimation of 
Cholinesterase activity in the diagnosis. In 1999 A.K.Janmeja, .M.Goyal and 
Manju  Sharma3 concluded that Cholinesterase ratio has a better 
discriminative capacity than lights criteria. The literature available on this 
study is less and therefore this study was planned to find out the efficacy of 
cholinesterase ratio in classifying pleural effusions and then comparing it 
with Abbreviated Lights Criteria (Pleural fluid to serum protein ratio). 
AIMS OF THE STUDY 
 
 
 
1) To evaluate the efficacy of Pleural fluid to Serum Cholinesterase 
Ratio in diagnosing pleural effusions. 
 
 
2) To Compare Pleural fluid to Serum Cholinesterase Ratio with 
Abbreviated Light’s Criteria. 
 
 
 
 
A REVIEW OF LITERATURE 
 
Pleural Effusions  
 
 Pleural Effusions has been known to clinical medicine since ancient 
times. Ancient texts of Indian Medicine-Ayurvedas had mentioned about 
drugs named “Kalyana sundara Rasha” which was found to be effective in 
treating conditions that caused water accumulations in the chest. But there 
was no direct mention of pleural effusions as such.  
 
Ancient Egyptian textbooks of medicine found in pyramids “Ebers 
Papyrus” now in the Library of Leipzig had a mention of adhesions of pleura 
in one case. Hippocrates (460-361BC) knew this entity which he thought as 
an inflammation of the lungs including the pleurae and termed it as 
parapneumonia. This was then known for many centuries to come. He also 
described Tuberculosis as Phthisis. 
 
Castiglioni, while reviewing other ancient texts found mention of 
clinical findings like noisy chest as if rubbing of leather straps, succession 
splash and snoring sounds in cases of pus in the chest while shaking the 
chest. These were diagnosed by applying ear to the chest directly. 
 
Avicenna’s “Canon of Medicine” which was translated into Latin and 
had been a foundation course of medicine in Universities of Europe from 
1250 AD to 1600 AD had mentioned about pleurisy which says that the 
signs of simple pleurisy are clear, fever is continuous, and there is sharp pain 
beneath the ribs, which sometimes is only felt when the patient breathe 
strongly. The third sign is difficulty and frequency of respirations, the fourth 
is a rapid and weak pulse rate, the fifth sign is the cough which at first is dry 
and then is accompanied by sputum.  
  
Thomas Sydenham considered parapneumonia similar to pleurisy 
except that it affected the lungs more. He was later called “Peripneumonia 
Notha” by his pupils. The adhesions of the surfaces of both pleurae (Brock 
Bank) was described by Geovani  Battista Mergagni . John Huxham in his 
essays of fever: because of it’s sluggish course and small fever and heat in 
contradistinction to pleurae- Para pneumonia where severe chest pain, acute 
high fever, breathing difficulty and spitting of blood was marked. In 1778 
Herman Boerhave noted in his “Aphorism”, that pleurisy is different and 
associated with pain which is increased on deep breathing and site   of pain 
is the pleura. William Cullen again described all inflammation under the 
heading  pneumonia .He  emphasized that though sometimes distinct yet in 
general no accurate limits can be placed  between pneumonia and pleurisy. 
 
Leopold Joseph Avenbrugger(1722-1809) invented chest percussion 
as a diagnostic  procedure . His published work, entitled Invention Novum 
became a landmark in history of medicine. But his works importance 
remained unknown until Jean Nicholas Covisart   (1755-1821) published a 
translation and commentary in 1808. 
 
Rene Theophile Hyacinthe Laennec(1781-1826) through his invention 
of the  stethoscope in 1816 gave us the modern concept of   pneumonia , 
pleurisy , pulmonary  tuberculosis and other pulmonary condition . He 
published his book on auscultation on 1819, titled Del’ Auscultation Mediate 
etc. This book introduced a diagnostic tool into medicine for the first time. 
He also wrote one of the most clear, accurate and almost completes account 
of chest diseases. 
 
Joseph Skoda (1805-1881) in 1839 added another useful diagnostic 
point to auscultation and percussion Skodiac resonance was described in 
relation to lobar pneumonia and over the air containing upper lobe above the 
level of a consolidated zone or the level of effusion (Brock Bank). Bowditch 
(1808-1892) was the first to tap pleural effusion.    
 
Pleura – Anatomy & Pathophysiology 
 
The Pleura consists of a single layer of mesothelial cells 
(mesothelium) supported by the submesothelial connective tissue. . There 
are two pleural sacs, one on the either side of the mediastinum. Each sac is 
invaginated from its medial side by the lung, so that it has an outer layer the 
parietal pleura and an inner layer, the visceral or pulmonary pleura. The 
layers are continuous with each other around the hilum of the lung and 
enclose between them the potential space of pleural cavity with a negative 
pressure. The normal pressure is -2 to -6mm 0f Hg.  
             
The pleural space serves as a coupling system between the lung and 
the chest wall.  The thin rim of the fluid that normally separates the parietal 
from the visceral pleura is thought to facilitate the movements of the lung 
within thoracic cavity. 
 
 
 The visceral pleura are more vascular than the parietal pleura. The 
later has sensory nerve receptors. Both the pleura can be the site of infection 
but usually pleural cavity and  its surfaces secondarily involved by the 
diseases of the adjacent structures which arise  from the heart, chest wall and 
the mediastinum, it is also involved in subdiaphragmatic  
pathology(subphrenic space, pathology of liver, spleen, pancreas , kidney 
etc.,  
 
The pleura is not just a simple envelope protecting the lung and acting 
as a permeability barrier, cells in the pleural space cooperate to maintain 
homeostasis through an intricate network of interactions. Particles, 
microorganisms and metastatic cells are able to alter the homeostatic state, 
resulting in the development of pleural effusions, fibrosis and neoplasms. 
 
The normal pleural fluid production is about 0.16-0.36ml/kg of body 
weight in each hemithorax. The systemic blood supply of the parietal pleura 
is thought to be the major source of normal pleural fluid. The parietal pleural 
microvessels are closer to the pleural space than those of the visceral pleura. 
The parietal pleural microvessels have a higher microvascular pressure 
because of their drainage into the systemic venules, while the visceral 
bronchial vessels drain into the low resistance pulmonary vessels. The liquid 
and the protein filtered from the pleural microvessels can flow across the 
mesothelial layer along the pressure gradient into the pleural space.  
 
The pleural space, by virtue of its size and surface area, its 
subatmospheric pressure, and its relative leaky borders, is clearly vulnerable 
to the accumulations of liquids.   
 Studies show that pleural fluid absorption occurs by bulk flow and not 
by diffusion. Compared with the visceral pleura the parietal pleura is more 
permeable to liquids and particles. The only possible exit of the pleural fluid 
is via parietal pleural stomata which directly link pleural fluid to pleural 
lymphatics. 
 
Pleural fluid analysis  
 
Pleural effusions can be caused by diseases in the chest, organs 
dysfunction or infections below the diaphragm, drugs and systemic diseases. 
In the U.S. approximately 2/3rd of the pleural effusions are due to CCF, 
pneumonia, malignancy and pulmonary embolism. In our settings most of 
the cases are due to infectious causes particularly due to tuberculosis. This 
may also be due to underdiagnosis of above mentioned conditions.  
 
Clinicians may first suspect a pleural effusion with the history, 
physical examination or by a chest x-ray film PA view. Then a lateral 
decubitus film or an ultrasound chest is done to confirm the findings. The 
next step is to do a diagnostic thoracentesis blind or guided. Here again not 
all cases need diagnostic thoracentesis. If   the patient has classical 
presentation of CCF or CRF the effusion resolves with treatment of primary 
causes. 
 
After thoracentesis the first step is to observe the colour, character and 
odour of the fluid. These will be helpful in making an initial diagnosis. A 
clear straw colored fluid suggests a transudate, but it can also be seen in 
paucicellular exudates. A serosanguinous appearance signifies a pleural fluid 
hematocrit of <1%. A gross bloody  effusion narrows the differential 
diagnosis to malignancy, Benign Asbestos pleural  effusion, Post Cardiac 
Injury Syndrome, pulmonary infarction, and trauma.  
 
 A haemothorax occurs most commonly in trauma, but can be also 
seen with invasive procedures, metastatic disease to pleura, and 
anticoagulation in pulmonary infarction and catamenial haemothorax. To 
diagnose haemothorax, pleural fluid haematocrit is compared with blood 
haematocrit which should be atleast 50% of the peripheral blood haematocrit. 
Then ICD is usually necessary.  
 
Withdrawal of milky or white fluid from the pleural space points 
towards either a chylothorax or a cholesterol effusion. Empyema can also 
simulate these conditions. To differentiate the empyema and lipid effusion 
centrifugation of the fluid is helpful. The former the cells settle down with a 
clear supernatant fluid in the top, while the latter will remains white. 
 
A longstanding bloody effusion may appear brown while brownish 
viscous fluid may represent an amoebic liver abscess rupturing into pleural 
space. A black pleural fluid may be due to Aspergillus Niger infection, 
whereas a yellow-green tinted fluid may  be due to rheumatoid pleural 
effusion . 
 
Anchovy paste appearing pleural fluid is virtually diagnostic of 
hepatopulmonary amoebiasis. When the pleural fluid smells like ammonia 
the diagnosis of urinothorax is established which is caused by obstructive 
uropathy. 
 
Determining whether the fluid is exudate or transudate is the first step 
in pleural fluid analysis, when evaluating patients with pleural effusion of 
unknown etiology.  
 
Exudative pleural effusion is caused by broad array of conditions 
which includes infections, neoplasms and inflammatory conditions. In 
contrast, transudative pleural effusion is caused by limited number of 
conditions; majority of which results from hydrostatic mechanism. 
 
Causes of Exudative Pleural effusion 
       
Infectious causes: 
                           Bacterial pneumonia 
                           Myco.tuberculosis 
                           Fungal pneumonia 
                           Atypical pneumonia 
                           Actinomycosis 
                           Nocardiosis 
                           Hepatic abscess and hepatitis 
                           Pancreatitis 
 
      Malignant conditions: 
                                  Carcinoma 
                                  Lymphoma 
                                  Leukemia 
                                  Mesothelioma 
 
     Inflammatory conditions: 
                                  BAPE (Benign Asbestos pleural effusion) 
                                  Pulmonary infarction 
                                  Sarcoidosis 
                                  PCIS (Post Cardiac Injury Syndrome) 
                                  ARDS 
                                  Uraemic pleurisy 
                                  Pancreatitis 
                                  Haemothorax 
            
Increased Negative pleural pressure: 
 
                                Atelectasis  
                                Trapped lung 
                                Cholesterol effusion 
Connective tissue disorders: 
                                Lupus pleuritis 
                                Rheumatoid pleurisy 
                                MCTD 
                                Churg Strauss syndrome 
                                Wegeners Granulomatosis 
Endocrine dysfunctions: 
                             Hypothyrodism  
                             Ovarian hyperstimulation syndrome 
 Lymphatic abnormalities: 
                             Malignancy 
                             Yellow Nail syndrome 
                             LAM 
                             Lymphangiectasis 
 
Movement of fluid from abdomen to pleural space: 
                            Acute Pancreatitis 
                            Pancreatic Pseudocyst 
                            Meigs syndrome  
                            Carcinoma, Chylous Ascites,   
                            Urinothorax 
                           
Causes of Transudative Pleural effusion: 
                             Congestive Cardiac Failure 
                             Cirrhosis 
                             Nephritic syndrome 
                             Peritoneal Dialysis 
                             Hypoalbuminaemia  
                             Atelectasis  
                               Constrictive Pericarditis 
                             Trapped Lung 
                              SVC Obstruction 
  It is important to discriminate Exudates and transudates accurately. 
Because of the prognostic significance of the conditions causing exudative 
effusion, the detection of exudates warrants additional diagnostic studies for 
most patients to determine the underlying cause of fluid formation.  
 
Conversely, a patient’s general clinical presentation is usually 
sufficient to determine the cause of transudative effusion without further 
diagnostic studies. 
        
   Exudative Pleural effusions are defined by the presence of a high 
concentration of large molecular weight constituents when compared to 
transudative effusions. Tests that determine the presence of exudates 
measure one or more of the constituents directly or by their effects on 
pleural fluid specific gravity.  Tests results have been used singly or in 
combination. The use of test in combination derives clinical importance of 
maximizing the sensitivity of the testing strategies to enhance the detection 
of exudates. Exudative effusions often signify the presence of clinically 
occult conditions that may have considerable prognostic significance. 
Therefore a screening strategy is employed wherein misclassification errors 
favours the overdiagnosis of exudative pleural effusions. As a rule, 
combination tests have a higher sensitivity, but a lower specificity than a 
single test strategy, even if single tests have similar diagnostic properties to 
the individual test components within the combination strategy. 
          
         Initially pleural fluid specific gravity and pleural fluid protein 
measurement was used to detect exudative pleural effusions, later to increase 
the sensitivity Lights &  coworkers established what is now known as 
“Lights criteria”1 The three original criteria  proposed were  
 
4) Pleural fluid to serum protein ratio > 0.5 
5) Pleural fluid to serum LDH ratio > 0.6 
6) Pleural fluid LDH >200 IU of upper limits of normal. 
 
Since different laboratories report different normal ranges of LDH, the 
last criteria  was later modified to an LDH concentration of greater than 
2/3rds of the upper limits of  normal for the  laboratory’s serum LDH test 
result. Later it was found that lights criteria had a sensitivity of 98% and 
specificity of 74% in identifying exudative pleural effusions from validation 
studies using pooled data from several primary investigations. In the recent 
years, other test having proposed to indicate a pleural exudates have 
included a pleural fluid cholesterol > 60 mg / dL 10,11 . A pleural fluid 
cholesterol > 45 mg / dL 12, a  gradient of less than 1.2 g / dL for the 
difference in the pleural fluid and serum albumin  level 13  , a pleural fluid to 
serum bilirubin ratio above 0.6 14  , and a pleural fluid to  serum 
cholinesterase ratio above 0.23 4,7 . 
Cholinesterases: a review 
 
              Two related enzymes have the ability to hydrolyze acetylcholine. 
One is acetylcholinesterase, which is called true cholinesterase or choline 
esterase1.true cholinesterase is found in erythrocyte, lung, spleen, nerve 
endings and the grey matter of brain. It is responsible for prompt hydrolysis 
of acetylcholine to release at the nerve endings to mediate transmission of 
neural impulse across the synapse. The degradation  of acetylcholine is 
necessary to the depolarization of the nerve so that it can be repolarised in 
the next conduction event.The other cholinesterase is acylcholine  
acylhydrolase; it is usually called pseudocholinesterase, benzoyl 
cholinesterase or  cholinesterase 2.Although it is found in the liver, pancreas, 
heart, white mater of the  brain and serum, its biological role is unknown. 
The serum enzyme is the one whose assay is clinically useful. 
 
The type of reaction catalyzed by both cholinesterases is 
 
                         
 
The two enzymes differ in specificity toward some substrate while behaving 
similarly toward others. The serum enzyme acts on benozylcholine but 
cannot hydrolyze acetylB- methylcholine; the red cell enzyme acts on the 
latter but not on the former. Only choline esters are split by the red cell 
enzyme; aryl or alkyl esters are not attacked. The red cell enzyme is 
inhibited by its substrate, acetylcholine, if present at concentrations about 
the 10-2 mol/liter; the serum enzyme is not inhibited by the substrate. 
 
              Both enzymes are inhibited by physostigmine and prostigmine, both 
of which contain quaternary nitrogen in their structures. These two 
compounds are typical competitive inhibitors, competing with the choline 
residue of acetylcholine for its binding site on the enzyme surface. Both the 
enzymes are irreversibly inhibited by the some organic phosphorus 
compounds, such as diiso-propylflurophosphate.The phosphoryl group binds 
very tightly to the enzyme site at which binding of acyl group normally 
occurs, thus preventing the attachment of acetylcholine. Both enzymes are 
inhibited by large variety of other compounds, among which are Morphine, 
Quinine, tertiary amines, citrate, borate and bile salts. The cholinesterase 
present in the normal sera can be separated by electrophoresis into 7 to 12 
bands, the number obtained depending upon the experimental technique 
used. The isoenzymes of acetylcholinesterase differ in molecular size and 
appear to be aggregates of different numbers of the same basic unit. Of more 
interest are the typical variants of the enzyme, characterised by the 
diminished against acetylcholine and the other substrates, which are found in 
the sera of a small fraction apparently healthy people. The gene controlling 
the synthesis of SChE can exist in many allele forms. Four of the  most 
common forms are designated as Eu1,Ea1,Ef1and Es1.Atleast 25 other 
forms exist,  and another gene locus is recognized (E2).The normal, most 
common phenotype is  designated as Eu1Eu1,or UU.The gene Ea1 is 
referred to as the atypical gene; the sera of  people homozygous for this gene 
(Ea1Ea1,=AA) are only weakly active toward most  substrates for 
cholinesterase and poses increased resistance to inhibition of enzyme  
activity by dibucaine. The Ef1 gene also gives rise to a weakly active 
enzyme but with increased resistance to fluoride inhibition. The Es1 gene (s 
for silent) is associated with absence of enzyme or the presence of a protein 
with minimal or no catalytic activity. The mutations that give rise to the 
typical and fluoride-resistant Cholinesterase variants involve a change in the 
structure of the active center. The variant isoenzymes (allelozymes) are less 
effective catalysts the usual form; the affinity of the enzymes for the 
substrates is reduced (i.e., Km is increased), and affinity for competitive 
inhibitors, such as dibucaine or fluoride, is similarly decreased. This gives 
rise to the characteristic dibucaine or fluoride resistant properties of the 
genetic variants that are exploited in their characterization. The homozygous 
forms, AA or FF, are found in only 0.3 to 0.5% of the white population; heir 
incidence among blacks is even lower. Inheritance of increased. 
Cholinesterase activity has also been reported in a few families. This is 
apparently due to increased production of the usual allelozyme. 
 
CLINICAL SIGNIFICANCE: 
 
Cholinesterase levels in serum are useful as a test of liver function, as 
an indicator of possible insecticide poisoning, or for the detection of patients 
with atypical forms of the enzyme. The spread of values encountered in 
apparently healthy people is rather wide, ranging between 4000 and 12000 
U/L at 37.C.The level in any given person is fairly constant; a fall in enzyme 
level of greater than 670U/L is significant at the 95% confidence level. 
Levels at birth are only one-fourth those of adults but reach adult levels by 
the second month of life. No enzyme is found in urine. Measurements of 
Cholinesterase activity can serve as sensitive measures of the synthetic 
capacity of the liver if a patient’s normal (baseline) level is known, which 
unfortunately the case is rarely. In the absence of known inhibitors, any 
decrease in activity in serum reflects impaired synthesis of the enzyme by 
the liver. A 30 to 50% decrease in level is obtained in acute hepatitis and in 
chronic hepatitis of long duration. Decreases of 50 to 70% occur in advanced 
cirrhosis and carcinoma with metastases to the liver. Essentially normal 
levels are noted in chronic hepatitis, mild cirrhosis, and obstructive jaundice. 
 
Decreased levels of serum enzymes are also found in patients with 
acute infections, pulmonary embolism, and muscular dystrophy, as well as 
after surgical procedures. After a myocardial infarction, the enzyme level 
decreases until the fifth day and then begins a slow rise to normal. 
Decreased levels are also found in chronic renal disease and in pregnancy. 
 
A marginal increase in enzyme levels may be observed in patients 
with nephrotic syndrome. Synthesis of albumin to replace that lost in the 
urine is accompanied by some synthesis of additional cholinesterase, 
although syntheses of the enzyme and albumin by the liver are independent 
of each other. Marginal increases in enzyme are also seen in thyrotoxicosis 
and hemochromatosis, in obese diabetic people, and in patients with anxiety 
and other psychiatric states. 
 
Among the organic phosphorus compounds that inhibit cholinesterase 
activity are many organic insecticides, such as Parathion, Sarin, and 
tetraethyl pyrophosphate. Workers engaged in agriculture and those working 
in organic chemical industries may be subjected to poisoning by inhalation 
of these materials or by contact with them. 
 
Obviously, if enough material is absorbed to inactivate all the 
acetylcholinesterase of nervous tissue, death will result. Both cholinesterases 
are inhibited, but the activity of the serum enzyme falls more rapidly than 
does that of the red blood cell enzyme. A 40% reduction in serum enzyme 
activity occurs before the first symptoms are felt, and a drop of 80% is 
required before serious neuromuscular effects become apparent. Near-zero 
or zero levels pf enzyme activity require emergency treatment with such 
enzyme reaactivators as pyridine-2-aldoxime. 
 
Succinyldicholine (suxamethonium) and mivacurium are drugs used 
in surgery as muscle relaxants. Because succinyldicholine is very similar to 
acetylcholine, it is also hydrolyzes by cholinesterase, and its physiological 
effect persist only long enough (30-50min) to meet the needs of the surgical 
procedure. In patients with low levels of enzyme activity or in those with the 
atypical, weakly active enzyme variants, destruction of this drug does   not 
occur rapidly enough, and patients may enter a period of prolonged apnea 
requiring mechanical ventilation until the drug is eliminated by other routes. 
Preoperative screening has been advocated to identify patients in whom 
suxamethonium administration may lead to complications. However, more 
often, the laboratory is asked to investigate patients and their relatives in 
whom suxamethonium sensitivity has been found. 
 
The degree of sensitivity varies with the phenotype of the patient and 
the dose of the   drug, size of the patient, and duration of surgery. There is a 
decline in total activity from individuals who are homozygous for the usual 
allele, through those who are heterozygous for the usual and a variant allele, 
those who are homozygous or heterozygous for variant allele, to zero in 
subjects in whom two “silent” alleles are paired. Subjects who poses one 
normal allele (i.e., who are heterozygous for the normal and variant allele) 
usually produce enough enzyme to protect them against suxamethonium 
sensitivity, whereas patient with paired variant allele (either as homozygote 
or heterozygote) shows various degree of sensitivity. 
 
Measurements of total SChE activity and determination of the 
“dibucaine number” and “fluoride number” are needed to characterize 
cholinesterase variants fully. The later parameters indicate the percentage 
inhibition of enzyme activity towards specified substrates in the presence of 
standard concentrations of these reagents. The average values of the 
dibucaine number for normals, heterozygotes and homozygotes (Ea1 gene) 
are 78, 60 and 16% respectively, when benzoylcholine is used as substrate. 
Dietz and associates reported values of 81 to 86, 67 to 80, and 8 to 35% 
respectively, with propionylthiocholine (PTC) as substrate. Analogous 
fluoride numbers with PTC as  substrate are 77 to 81, 67 to 79 and 54 to 
65% respectively Phenotypes most susceptible  to apnea after suucylcholine 
administration are AA,AS,FF,FS,SS,AF and to some extent  UA.  
 
Cholinesterase levels in cerebrospinal fluid are very low. The total 
activity present in  fluids from healthy individuals is about 17+/-4 U/L.Both 
the serum and red blood  enzyme forms can be detect ed, with the serum 
form present in the greater concentration.  Elevation of Cholinesterase 
activity are appreciable in diseases involving destruction of brain 
parenchyma, in brain tumors and in brain abscess, in hydrocephalus (to 
40U/L), in Guillain-Barre disease (to 60U/L), and often in meningitis and 
multiple sclerosis. In other neurological and non neurological diseases, 
enzyme levels are normal or any changes are too nonspecific and 
inconsistent to be of mush value in diagnostic work.  Cholinesterase activity 
is independent of routine concentration and of leukocyte count,   the 
leukocyte containing no enzyme activity.  
 
METHODS FOR DETERMINATION OF CHOLINESTERASE 
ACTIVITY 
 
         The hydrolysis of acetylcholine, the substrate used in older methods, 
results in the formation of 1 mol of hydrogen ions for each mol of substrate 
reacted. In manometric method, these hydrogen ions react with bicarbonate 
buffer to release carbon dioxide, which is then measured. In the 
potentiometric procedure of Michel, the decrease in pH during the course of 
a fixed reaction period is measured. The acid formed can be titrated with a 
pH-stat. If pH indicators that change colour in the pH range of 6-8.5 
(bromothymol blue, m-nitrophenol) are incorporated into the reaction 
mixture, the change in colour, measured spectrophotometrically, can serve 
as a measure of enzyme activity. A number of kits and test papers devised 
for testing for enzyme activity in the field are based on this principle. 
 
In the procedure of de la Huerga and colleagues, the quantity of 
untreated acetylcholine remaining after a 60 min reaction period at 37.C is 
measured. The ester is reacted with hydroxylamine to form the hydroxamate 
derivative; the complex forms an orange-brown complex with ferric ions in 
acid solution that can be measured photometrically at 540nm. Kalow and 
Genest proposed benzyl choline as substrate and measured the decrease in 
sorbents of the substrate at 240 nm. 
 
    Contemporary methods used acylthiocholine esters as substrate. The 
substrate are hydrolyzed at approximately the same rate as cholineesters,and 
the thiocholine formed  can be measured by reaction with chromogenic 
disulfide agents such as DTNB (Ellman’s  reagent)22 or 4,4’-dithiodipyridine. 
The iodide salts of acetyl-, propionyl-, and butryl thiocholine all have been 
used as substrate. The reactions for butryl thiocholine with DTNB as the 
chromogen are given in equations. 
 
 
 
The DTNB reaction produces a color that can be measured at 410nm. If 4,4’- 
dithiodipyridine is used as a  chromogen, mercapopyridine is formed; this 
immediately  tautomerizes to thiopyridine, which absorbs at 344nm.  
 
DETERMINATION OF SERUM CHOLINESTERASE ACTIVITY 
 
Principle:  
 
Activity of SChE is determined from the rate of hydrolysis of 
propionyl-thiocholine in the presence of DTNB. The reaction of thiocholine 
product with colourless DTNB forms coloured 5-MNBA, which is measured   
spectrophotometrically at 410 nm. Dibucaine or fluoride inhibition can be 
estimated by performing concurrent assays in which dibucaine or fluoride is 
present in the substrate mixture. Percent inhibition is evaluated by   
comparison of activity in the inhibited system with that of uninhibited 
system.  
 
Specimen: 
       
Serum is the sample of choice. Enzyme activity is stable for several 
for several weeks whether the specimen is stored at room temperature or 
under refrigeration. Moderate hemolysis does not interfere if separated 
serum has been centrifuged to remove RBC ghosts. 
 
Reagents: 
      
1. Phosphate buffer, pH 7.6, ionic strength 0.1 in water.  
2. Propionylthiocholine iodide (PTCI), 20mmol/L in water. 
3. Dibucaine, 0.3mmol/L in water. 
4. Sodium fluoride, 40mmol/L in water. 
5. DTNB-buffer (Color Reagent). 0.423mmol/L in Phosphate buffer. 
6. Substrates:   
a. Uninhibited reaction. Mix equal parts of PTCI (Reagent 2). 
b. Dibucaine-inhibited reaction. Mix equal parts of PTCI and 
Dibucaine Solution (Reagent 3). 
c. Fluoride- inhibited reaction. Mix equal parts of PTCI (Reagent 
2) and Fluoride Solution (Reagent 4). 
7. Quinidine sulfate, 0.5 g/dl in water. 
  
Final concentrations in assay mixtures, in mmol/L, are PTCI, DTNB, 
0.254; phosphate, 25; and (when present) dibucaine, 0.03 or fluoride, 4. 
 
Procedure: 
1. Dilute serum 100-fold with water. 
2. For each inhibited or uninhibited assay, prepare two 16x 125-mm 
tubes, labeling one B (blank) and U (unknown). 
3. Add to U and B tubes, 3.0mL DTNB-buffer and 1.0 mL of 
appropriate substrate mix. 
4. Warm tubes at 37deg C for 5 min. 
 
5. Without removing the tube from the bath and starting timer on 
addition, add to u tube 1.0 mL of diluted serum. Mix and allow 
remaining at 37deg C for 3 min. 
6. Add, to U and B tubes, 1.0 mL Quinidine sulfate. Mix. 
7. Add to tube B, 1.0 mL diluted serum and mix. 
8. As color quickly fades, transfer contents of corresponding U and B 
tubes to 1 –cm cuvets and proceed promptly to read absorbance. 
9. Read absorbance of U against B set to zero absorbance at 410 nm. 
Under these circumstances absorbance of U represents absorbance 
∆A/3 min. 
 
Calculations: 
Uninhibited reaction: 
 
       U/L =   ∆A/min                     = ∆A/min x 14710 
                   13.6 x 6.0/0.01 
      Where 
                  ∆A/min = Au/3 min 
      13.6 = L x µmol -1 x cm-1, the micromolar absorption coefficient of  
5-MBNA. 
    6.0  =  total value of reaction system (mL). 
0.01 =  volume of serum in reaction system 
 Percentage of inhibition  
          % of inhibition = (1- Au of inhibited system / Au of uninhibited 
system) x 100. 
 
Comments: 
 
The original report describes alternatives of timing, temp and 
standardization.  
  Reference intervals for genetic variants are also presented. 
 
Reference Interval: 
For the genotype Eu1Eu1, the mean +/– SD for foregoing method is 8440 
+/ – 1780 U/L. 
 
Reference:  
 
Dietz A.A., Rubinstein, H.M., Lubrano, T.: colorimetric determination 
of serum cholinesterase and its genetic variants by 
propylthiocholineedthiobis (nitrobenzioc acid)   procedure. .Clin. Chem 
19:1309-1313, 1973. 
 
 
 
  
 
       
  
MATERIALS AND METHODS 
  
This study is a Prospective case study undertaken during a period of 8 
months (Feb  2005-Sep 2005) done at Institute of Thoracic Medicine, 
Chetput, chennai-31 & Dept of  Thoracic Medicine, Madras Medical 
College and Govt.General Hospital, Chennai-3 . 
 
            The criteria for the patients taken up for study are as follows: 
 
Inclusion criteria: 
                    
                                1. Tuberculosis pleural effusions 
                                2.  Malignant Pleural effusions 
                                3. Para pneumonic effusions 
                                4. Effusions with cardiac failure 
                                5. Effusions with renal failure    
 
                                          Exclusion criteria: 
                   
1. Pleural effusion with more than one etiology 
2. Pleural effusion in patients with hepatic disease 
                            3.  Pts on Oral contraceptives 
4. Pts on anticancer drug, MAOls, Neostigmine 
5. Pts on chlorpromazine 
6. Pleural effusion in patients pregnant 
7. Pts with H/O exposure to pesticides. 
   (organophosphorous compounds) 
A study population 80 patients with clinical and radiological evidence 
of Pleural effusion of diverse etiology were studied after exclusion. A 
relevant history and detailed clinical examination was done. The following 
investigations were done. 
 
Blood: Hemoglobin, Total count, Differential count, ESR. 
Routine urine examination. 
Chest Roentgenogram PA and Lateral View. 
Sputum for AFB smear.  
Sputum Cytology for Malignant Cells. 
Mantoux test. 
 
Then Thoracentesis was performed in each case with due aseptic 
precautions. Care was taken not to let fluid to mix with blood .About 10mL 
to 15mL of pleural fluid was aspirated in each case and Specimen was stored 
at 20-80 Celsius. Within half an hour 10ml blood was collected in 
vaccutainer and centrifuged and sera stored at 20-80 Celsius. 
 
The pleural fluid was analyzed as follows 
 
1. Initially color of the fluid was noted. 
2. Pleural fluid was sent for biochemical analysis for protein, sugar, 
LDH. 
3. Pleural fluid was sent for microbiological analysis for Grams 
stain, AFB smear and Culture and NT culture in selected cases. 
4. Pleural fluid was sent for cytology for Malignant Cells.  
5. Then cholinesterase activity in the pleural fluid and sera was 
assayed by the methods described by Dietz 6 by using Randox 
Butyrylcholinesterase kit by kinetic calorimetric method 
(Ellman’s reaction 22 .).  
6. Similarly the serum protein, sugar, LDH and cholinesterase 
activity was analyzed. 
 
 
        
 
        
  
 
 
 
 
 
 
           
   
 
 
 
 
          
    
 
OBSERVATION AND RESULTS 
 
         
In the present study 80 cases of patients who had pleural effusions of 
diverse etiology was selected. The clinical, radiological and relevant 
laboratory investigations and diagnostic pleural aspiration were done in all 
these cases. The pleural fluid was analyzed by looking for the color of the 
fluid, microscopy, cytology and relevant  biochemical parameters which 
included the estimation of serum cholinesterase and  pleural fluid 
cholinesterase. 
 
The patients were divided into 5 groups depending on the etiology of 
the pleural effusion. They are tuberculosis, malignant, parapneumonic, CCF, 
and CRF, the first three being exudates and the last two transudates. The 
criteria for tuberculous effusion included a clinical presentation, history of 
contact, radiological evidence, and sputum for AFB and culture.  For 
transudative effusions cardiac and renal decompensation was taken into 
account. The inclusion criteria were pleural effusions with protein content 
less than 3 Gm% and no evidence suggestive of inflammatory or infectious 
cause. 
 
For the malignant group, the clinical presentation, age, sex, smoking 
habit, loss of weight, clubbing, color of the pleural fluid, rate of 
reaccumulation, and cytopatholgical and histopathological confirmation was 
looked for. For the diagnosis of effusion in pneumonia cases age, sex, onset 
of the fever, color of the pleural fluid, cell count, presence of pus cells and 
organisms were taken into account. 
 
Etiological Group and their Distribution 
 
Table 1 
Group Type No of cases
A Tb 47 
B Malignant 8 
C Parapneumonic 5 
D CCF 3 
E CRF 17 
 
• Exudates       60 ( A,B,C) 
• Transudates  20 ( D,E) 
 
 Exudate
13%
8%
79%
MALIGNANT
PARAPNEUMONIC
TB
 
 
 Transudate
15%
85%
CCF
CRF
 
 
             Out of the 47 cases in group A, 33 cases complained of 
breathlessness, 28 cases complained of fever, 6 cases had haemoptysis, 32 
had cough. In group B, 4 cases complained of breathlessness, one case had 
fever, all the cases had cough and 2 cases had story of hemoptysis.  In group 
C all the cases had History of fever, 4 cases had cough, and 2 cases had 
breathlessness. In groups D and E breathlessness and cough were the 
predominant complaints. The signs were as shown in the table below  
 
Table 2 
 
SIGNS A B C D E 
CLUBBING - 3 - - - 
ANEMIA 20 4 1 2 17 
PEDAL EDEMA - 1 - 3 15 
LYMPHADENOPATHY - 2 - - - 
 
On analysis of the cell count it was found that WBC count was within 
4000 to 10000 cells/cu mm in group A and in Group C out of 5 cases 4 cases 
had WBC count more than 10000 cells/cu mm. 
Table 3 
 
Total WBC Count A B C D E
> than 4000 cells - - - - - 
4000-10000 cells 47 8 1 - - 
>than 10000 cells - - 4 - - 
 Then ESR was found to be elevated in Group A, B, and C groups, the 
highest being in the group B. It was measured using Westergren’s measured. 
Mantoux test was positive in all the cases in group A. 
 
Sputum examination was done in each case for AFB and malignant 
cells. For AFB smear sputum was collected according to RNTCP guidelines 
i.e. Spot-early morning- spot. It was positive in 3% of suspected tuberculous 
pleural effusion cases. For the detection of malignant cells in sputum was 3 
sputum specimens collected in 70% alcohol on successive 3 days and sent 
for cytological analysis by pap method. In this study about 2 cases turned 
out to be adenocarcinoma.  
 
Chest Roentgenogram was done in all cases for the confirmation of 
clinical diagnosis. Pleural fluid examination was done in all the cases. First 
of all the color of the  fluid was noted if there was any bleeding noted then 
the first sample was discarded and  then the next sample was taken for 
analysis. 
 
Age distribution shown in the figure below: 
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Color of Pleural Fluid: 
Table-4 
 Group A B C D E 
Clear - - - 3 15 
Straw colored 47 2 2 - 2 
Hemorrhagic - 6 - - - 
Purulent - - 3 - - 
 
 
 
 
 
In this table it is observed that the color of the fluid is straw colored in 
all the cases  in group A where as it is hemorrhagic in most of the cases in 
group B.  
 
Regarding the lymphocyte count most of the patients in group A had 
above 60% where as in group D and E count was below 50% in all the cases. 
For detecting malignant cells in the pleural fluid, the fluid was centrifuged at 
1000rpm and the deposit  was taken for smear and staining with H&E stain.  
 
The mean cholinesterase level is shown in the figure below: 
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80 pleural effusion patients were evaluated after exclusion of 4 
patients, one with a chylothorax , two patients with more then one etiology 
and one patient with  liver disease.  60 cases fall in group A, B and C. They 
form the exudative group. Rest of  the 20 cases fall in the transudative group 
i.e. group D and E.  
 
Group Type No of cases % 
A Tb 47 78.34 
B Malignant 8 13.3 
C Parapneumonic 5 8.33 
D CCF 3 15 
E CRF 17 85 
 
  In the present study 2 parameters are compared to effectively diagnose 
whether the  pleural fluid aspirated is an exudate or a transudate.  
 
1. Pleural fluid to serum cholinesterase ratio. 
2. Pleural fluid to serum protein ratio (Abbreviated Lights criteria). 
 
By using Pleural fluid to Serum Protein ratio (Abbreviated Lights 
criteria). 
Table 5 
Exudate / 
Transudate 
Clinical/Xray/Lab 
methods 
Pleural fluid to serum 
protein ratio 
Exudate 60 65 
Transudate 20 15 
 
       Using Abbreviated Light’s Criteria 5 cases of transudates were 
misclassified as exudates.  
 
Pleural fluid to Serum Cholinesterase ratio. 
 
Table 6 
Exudate / 
Transudate 
Clinical/Xray/Lab 
methods 
Pleural fluid to serum 
cholinesterase ratio. 
Exudate 60 58 
Transudate 20 22 
 
Using  Pleural fluid to serum Cholinesterase ratio 58 cases of exudates 
were correctly classified. About 2 cases of exudates were misclassified  as 
transudates. 
  
Correlation between the Protein and Cholinesterase is shown in the 
figure below:  
  
pro_ratio
cho_ratio
Correlation between Cholinesterase & Protein
 
Statistical analysis was done by using Pearson’s chi-square tests, 
correlation study by continuity correlation and likelihood ratio by Fisher’s 
exact test. They showed that the  sensitivity and specificity using pleural 
fluid to serum protein ratio was 91.75% and  specificity of 75% respectively 
where as for pleural fluid to serum cholinesterase ratio  sensitivity and 
specificity were 96.7% and 90% respectively. 
   
Comparison with other studies: 
Table-7 
Efficiency Misclassification 
Parameters Present 
Study 
Manju,Gupta 
et al 
Present  
Study 
Manju,Gupta 
et al 
Abbreviated Light’s 
Criteria 
91.7% 86.36% 8.3% 13.63% 
Pleural fluid to serum 
Cholinesterase ratio 
96.7% 98.18% 3.3% 1.82% 
 
 This table shows that the present study is almost consistent with 
Manju Sharma et al3.  cabrer et al16  in his study of 158 cases concluded that 
98.7% of the cases were diagnosed correctly using pleural fluid to serum 
Cholinesterase ratio and concluded that Pleural fluid to serum Cholinesterase 
ratio is the most accurate criteria in differentiating transudates and exudates.  
 
 
DISCUSSION 
 
In the past, transudates were separated from exudates by the specific 
gravity,  cell count and the presence or absence of clotting of fluid. In 1972, 
Light et al1 developed criterion for the diagnostic separation of transudates 
from exudates. Thereafter it was found that Light’s criteria misclassified a 
large number of effusions which may lead to unwarranted invasive 
interventions in about 20% to 30% of patients with transudates 20,21.  
Therefore some doubts were cast on the universal applicability of  Light’s 
criteria.  Subsequently, Romero S, Candela A, Martin C, et al 15 used 
modified Light’s criteria  using new cut-off values. However Vives et al 21 
found that change in the classic Light’s  criteria with different cut-off values 
offered no advantage in differentiating exudates and transudates. In the 
present study the diagnostic efficacy of pleural fluid and serum 
cholinesterase ratio is compared with abbreviated  Light’s criteria. 
 
Many biochemical parameters like pleural fluid cholesterol, bilirubin, 
albumin,  adenosine deaminase 25, 26 , (MDA) malondialdehyde and their 
ratios with the serum  values have been used to differentiate the types of 
pleural effusions. Cholesterol is constantly present in pleural effusion and is 
high level is observed in tubercular effusion. 
 
However, extraordinarily high level of  Cholesterol in pleural fluid is 
independent of it’s value in serum 24. Gupta et al 27 studied pleural fluid 
cholesterol and serum cholesterol  ratio in 70 cases of pleural effusion and 
found that the estimation was not only cost  effective but also extremely 
useful parameter to distinguish transudate from exudate. 
 Despite these various diagnostic procedures, in 10 to 20% of cases the 
cause of pleural effusion was uncertain. According to Eduardo et al 2 studied 
about 153 cases and was able to classify about 98.7% of pleura effusions and 
concluded that pleural fluid to serum cholinesterase ratio was the most 
accurate criteria for differentiating transudates and exudates. 
 
In our settings usually pleural fluid protein and its ratio with the serum 
protein is done mainly to differentiate exudates from transudates because of 
its economic feasibility and its ready availability. Therefore it was thought 
that it would be prudent if  the pleural fluid to serum cholinesterase ratio was 
compared with pleural fluid to serum protein ratio( Abbreviated Light’s 
criteria).      
           
Using a cut-off value of 0.23 7 to differentiate exudates from 
transudates it was found that  pleural fluid to serum cholinesterase ratio was 
significantly higher in exudates than transudates.   In the present study the 
mean pleural fluid cholinesterase in exudates was 2589 and in transudates 
was 605.3. The difference between the two is statistically significant  (P 
value < 0.001). The mean pleural fluid to serum cholinesterase ratio was 
0 .72 in exudates and in transudates is  0.17. According to M.Sharma et al3    
pleural fluid to serum cholinesterase ratio was 0.79 and 0.14 for exudates 
and transudates respectively in their study. About 86% of cases were in the 
3rd to 6th decade of life and male to female ratio being 1 : 0.75. There are a 
total of 60 cases of exudative effusion of diverse etiology which includes 
tuberculous effusion, malignant and effusions associated with pneumonia. 
There are about 20 cases of transudative effusions out of which 17 cases are 
due to CRF and the rest are due to CCF. 
 
 
While comparing pleural effusion using Abbreviated Light’s criteria 
(pleural  fluid to serum protein ratio), out of 60 cases of exudative effusion, 
only 55 cases were identified as exudates, rest of the 5 cases were 
misclassified as transudates, giving an efficiency ratio of 91.7%.  
 
But while comparing pleural effusion using pleural fluid to serum 
cholinesterase ratio, out of 60 exudative effusions, 58 cases were correctly 
identified  as exudates, rest of the 2 cases were misclassified, giving an 
efficiency ratio of  96.7%. The maximum misclassification according to the 
present study is by  applying Abbreviated Light’s criteria. When compared 
to other major studies, the present study is almost consistent with their 
findings. 
 
The present study has revealed that the pleural fluid to serum 
cholinesterase ratio is more effective than the pleural fluid to serum protein 
ratio in diagnosing exudates. The sensitivity of pleural fluid to serum 
cholinesterase ratio in diagnosing exudative pleural effusion should be 
evaluated using larger studies.  
 
Therefore is recommended that  pleural fluid to serum cholinesterase 
ratio estimation can be done in all cases of pleural effusions to differentiate 
between exudates and transudates. 
  
                   
 
 
CONCLUSION 
 
 
1) The results of the present study suggest that pleural fluid to 
serum cholinesterase ratio is one of the most accurate criteria in 
classifying pleural effusion. 
2) Pleural fluid to serum cholinesterase ratio has more 
discriminatory   capacity than the pleural fluid to serum protein 
ratio (Abbreviated lights  criteria) for the same purpose. 
3) It is also simple to perform as well as more economical than the 
tests done for light’s criteria. 
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MASTER CHART 
 
Cholinesterase Protein Sl. 
No Name 
Age/ 
Sex Pleural fluid serum 
Ratio Pleural 
fluid serum 
Ratio E/T Dia. 
1 Ramakrisnan 19/m 2847 3711 0.76 5.5 4 1.3 E TB 
2 Tamilarasi 28/f 2442 2858 0.85 4.4 5.2 0.85 E TB 
3 Suresh 39/m 3185 1915 1.66 8.4 6.4 1.3 E TB 
4 Ravi kumar 52/m 2238 3199 0.69 4.2 5 0.84 E TB 
5 Pandian 30/m 1732 1439 1.48 4.8 4.4 1.09 E TB 
6 Dravidachelvan 44/m 3906 7697 0.5 5.3 4.6 1.15 E TB 
7 Srinivasan 50/m 2055 2601 0.79 6.2 7.2 0.86 E TB 
8 Anadavel 33/m 3346 2863 1.16 5.8 6.2 0.94 E TB 
9 Arulmary 30/f 2734 5935 0.46 5.5 4.2 1.3 E TB 
10 Perumal 38/m 2407 3368 0.71 6.2 7.3 0.84 E TB 
11 Priya 27/f 3164 3565 0.88 6.1 7.2 0.83 E TB 
12 Sasikala 14/f 2731 3684 0.74 3.3 6.4 0.5 E TB 
13 Ganesan 40/m 4637 2493 1.86 5.3 6 0.88 E CA 
14 Jayashanker 30/m 3975 5458 0.72 5.7 6.7 0.85 E TB 
15 Sarojamma 60/m 2409 7450 0.32 4.4 6.2 0.7 E TB 
16 Sasikumar 29/m 1868 3117 0.59 4.1 4.8 0.85 E TB 
17 Prabhu 23/m 4703 9293 0.5 4.9 5.2 0.94 E TB 
18 Balasubramani 22/m 4791 6570 0.73 3.8 4.6 0.83 E CA 
19 Adhi 40/m 3371 8250 0.41 3.9 4.2 0.93 E CA 
20 Rajathi 55/f 1185 7935 0.15 2.5 5.4 0.46 T CRF 
21 Vadival 45/m 2204 5068 0.43 4.7 4 1.18 E TB 
22 Pandurangan 65/m 300 2349 0.13 2.2 5.6 0.39 T CCF 
23 Meenakshmi 17f 4584 6503 0.7 4.5 5 0.28 E TB 
24 Shanthi 43/f 2265 3057 0.74 3.8 4.2 0.9 E TB 
25 Mesakrajan 18/m 1231 1075 1.14 4.6 5.2 0.88 E TB 
26 Tulasi 25/f 2191 2092 1.04 5.2 5.8 0.9 E TB 
27 Sivakami 55/f 4511 4180 1.07 6.2 6.8 0.91 E TB 
28 Gandhi 41/m 626 2832 0.22 2.1 4.9 0.42 T CCF 
29 Kannan 58/m 4430 7912 0.55 4.7 5.3 0.89 E TB 
30 Minnal 38/f 1171 4135 0.28 4 4.3 0.93 E TB 
31 Panchalai 50/f 1654 4918 0.33 4.4 4.8 0.92 E TB 
32 Sher bahadur 55/m 2562 5022 0.51 5.1 6.2 0.82 E TB 
33 Palayam 60/m 3183 7964 0.39 4.1 5 0.82 E CA 
34 Shanthi 32/f 2656 4915 0.54 4.6 5.1 0.9 E TB 
35 Prabhakar 36/f 2408 3617 0.66 6.1 6.5 0.94 E TB 
36 Rani 29/f 3099 7381 0.42 3.9 4.9 0.79 E PARA 
37 Gopinath 25/f 3449 5043 0.68 5.9 6.3 0.93 E TB 
38 Vembuliammal 80/f 4636 7807 0.59 6 5.9 1.01 E TB 
39 Arulmary 30/f 2501 3780 0.66 5.7 6 0.95 E TB 
40 Devanathan 54/m 3412 4080 0.84 4.7 6.4 0.73 E CA 
41 Bhadrachalam 56/m 1114 1775 0.63 6.2 6.7 1.08 E TB 
42 Elango 33/m 2927 4210 0.69 4.9 5.5 0.89 E PARA 
43 Gyananavel 28/m 2021 3117 0.65 3.9 5 0.78 E TB 
44 Fathima 34/f 1914 3074 0.62 4.7 5.3 0.89 E TB 
45 Raghu 22/m 1980 1839 1.07 5.8 6 0.97 E TB 
46 Palani 42/m 1904 1787 1.06 5.2 5.9 0.88 E PARA 
47 Kaliammal 49/f 1391 2680 0.52 5 5.2 0.96 E TB 
48 Raji 33/f 1324 3653 0.36 5.4 5.6 0.96 E TB 
49 Vasantha 43/f 1750 2756 0.63 4.3 5.2 0.83 E TB 
50 Govindasamy 62/m 2954 2703 1.09 5.9 6.3 0.94 E TB 
51 Anbu 18/m 1820 1636 1.11 5 5.5 0.9 E PARA 
52 Kumar 32/m 2409 2452 0.98 4.7 5.9 0.79 E TB 
53 Vasanthi 33/f 1661 1782 0.93 5.2 5.8 0.89 E TB 
54 Devaraj 52/m 300 1299 0.23 2 5 0.4 T CRF 
55 Padmalakshmi 54/f 585 2598 0.22 1.4 4.8 0.29 T CRF 
56 Arumugam 59/m 1578 2900 0.54 5.8 7.2 0.8 E CA 
57 Indra 31/f 450 2006 0.22 2.2 5.6 0.39 T CRF 
58 kesavan 39/m 3804 4900 0.78 4.8 6.9 0.69 E CA 
59 Sulochona 52/f 280 1345 0.21 2.7 6.1 0.44 T CRF 
60 Devi 42/f 310 1600 0.19 2.3 6 0.38 T CRF 
61 Periyasamy 57/m 225 1046 0.21 2 5.4 0.37 T CRF 
62 Murugesan 39/m 330 1863 0.18 2.6 5.5 0.47 T CRF 
63 Kalpana 24/f 425 2153 0.2 2.7 5.8 0.47 T CCF 
64 Mohan 48/m 250 1700 0.15 2.2 5.3 0.41 T CRF 
65 Venu 50/m 380 1890 0.2 3 6.5 0.46 T CRF 
66 Kavitha 28/f 200 1008 0.19 2.9 5.9 0.49 T CRF 
67 Munisamy 61/m 254 1238 0.21 3.2 6.6 0.48 T CRF 
68 Ravi 47/m 670 4989 0.13 4.4 7 0.42 E TB 
69 Rani 52/f 1852 3108 0.59 4.2 6.9 0.6 E TB 
70 Shanthi 29/f 1250 2415 0.51 4.6 6.8 0.67 E TB 
71 Rajendiran 45/m 1666 2896 0.57 4 5.9 0.48 E TB 
72 Murugantham 30/m 1113 1780 0.62 3.8 6.6 0.57 T CRF 
73 Rafiq 21/m 1314 2074 0.6 4.7 5.8 0.79 E TB 
74 Sujatha 29/f 608 4623 0.13 2.7 6.1 0.44 T CRF 
75 Vidya 35/f 1962 3144 0.62 4.4 6.3 0.66 T CRF 
76 Ramamuruthy 41/m 1896 2968 0.63 3.9 5.9 0.65 E PARA 
77 Chinnaponnu 25/f 1413 2880 0.49 4 6.7 0.59 E CA 
78 Rajalakshmi 19/f 1510 2545 0.19 4.7 7.1 0.66 T CRF 
79 Velu 29/m 1456 2603 0.15 3.9 6.2 0.62 T CRF 
80 Brinda 40/f 1319 2213 0.22 3.8 6.1 0.62 T CRF 
 
 
  
 
 
 
